Skip to content

Exploring curcumin's role in easing irritability in kids with autism

Curcumin as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13881401
Enrollment
60
Registered
2023-11-23
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder Mental and Behavioural Disorders

Interventions

Permuted randomized blocks (blocks of four, allocation ratio 1:1) will be used by an independent party, who was not involved elsewhere in the trial, to generate the randomization codes. Allocation con

Sponsors

Roozbeh Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children aged 4–12 years 2. Male or female 3. Outpatients referred to clinic with probable autistic signs and symptoms and who meet the DSM-5 criteria

Exclusion criteria

Exclusion criteria: 1. Concurrent prominent psychiatric disorder 2. Preexisting medical conditions (in particular epileptic disorders and febrile seizures) 3. Intellectual disability (IQ <70) 4. History of drug or alcohol abuse 5. History of tardive dyskinesia 6. History of taking antipsychotic medication within 6 months prior to enrollment

Design outcomes

Primary

MeasureTime frame
Irritability is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12

Secondary

MeasureTime frame
1. Lethargy/social withdrawal is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12 2. Stereotypic behavior is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12 3. Inappropriate speech is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12 4. Hyperactivity/noncompliance is measured using the Aberrant Behavior Checklist (ABC) at baseline, week 4, week 8, and week 12

Countries

Iran

Contacts

Public ContactMohamad Farhadi-shahi
mohammad.farhadi.md@gmail.com+98 (0)2122324489

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026